Sanofi-Aventis
Also known as: Bioverativ - a sanofi company | Bioverativ, a Sanofi company | Clinical Science & Operation - sanofi-aventis | MCM Vaccines B.V. | Pasteur Merieux Connaught | Principia Biopharma, a Sanofi Company | SANOFI AVENTIS | sanofi-aventis administrative office | Sanofi-aventis administrative office Argentina | Sanofi-aventis administrative office Brazil | Sanofi-aventis administrative office France | Sanofi-aventis administrative office Gulf | sanofi-aventis Hungary | Sanofi-aventis, Hungary | sanofi-aventis Japan | Sanofi Aventis K. K. | Sanofi Aventis K.K. | sanofi-aventis, Sweden | Sanofi-aventis Turkey | Sanofi-aventis, Turkey | SANOFI AVENTIS US | SANOFI-AVENTIS US | Sanofi-Aventis U.S. LLC | SANOFI-AVENTIS U.S. LLC | sanofi-avents | Sanofi Pasteur | Sanofi Pasteur, a Sanofi Company | Sanofi Pasteur Asia Pacific | Sanofi Pasteur China | sanofi pasteur Inc | Sanofi pasteur Inc. | Sanofi Pasteur Inc. | Sanofi Pasteur, Inc | Sanofi Pasteur, Inc. | Sanofi Pasteur India Pvt Ltd | Sanofi Pasteur K.K | Sanofi Pasteur Limited | Sanofi Pasteur Ltd. | Sanofi Pasteur MSD | Sanofi Pasteur Philippines, Inc. | Sanofi Pasteur Russia | Sanofi Pasteur SA | Sanofi Pasteur SA. | Sanofi Pasteur Singapore | Sanofi Pasteur South Korea | SANOFI US SERVICES | Sanofi US Services, Inc | SPMSD
Highest phase reached
Phase 4
First clinical trial
Mar 1, 1995First marketed drug
Jun 1, 1991First NDA
Dec 31, 1991Last known activity
Oct 31, 2025
Timeline
1990s
- Jun 1, 1991
Sanofi-Aventis— Founded
2000s
- Jan 1, 2002
Lorex Pharmaceuticals— Acquired
- Jan 1, 2004
Sanofi-Synthelabo— Acquired
- Apr 16, 2004
insulin glulisine— NDA Secondary Org
- Jan 1, 2008
Acambis— Acquired
- Jan 1, 2009
Chattem— Acquired
- Apr 15, 2009
BiPar Sciences— Acquired
- Jul 27, 2009
Shantha Biotechnics Limited— Acquired - Oct 1, 2009
Fovea Pharmaceuticals— Acquired
2010s
- Jun 30, 2010
TargeGen— Acquired
- Sep 27, 2010
VaxDesign— Acquired
- Jan 1, 2011
Genzyme— Acquired
- Oct 1, 2011
Topaz Pharmaceuticals Inc— Acquired
- Aug 3, 2012
aflibercept— Marketing Organization
- Aug 3, 2012
aflibercept— NDA Organization
- Aug 1, 2017
Protein Sciences Corp— Acquired
- Jan 22, 2018
Bioverativ Therapeutics Inc.— Acquired
- Jan 29, 2018
Ablynx— Acquired
- Dec 9, 2019
Synthorx, Inc.— Acquired
2020s
- Aug 17, 2020
Principia Biopharma, Inc.— Acquired
- Nov 2, 2020
Kiadis Pharma— Acquired
- Jan 11, 2021
Kymab Limited— Acquired
- Apr 9, 2021
Tidal Therapeutics— Acquired
- Aug 3, 2021
Translate Bio, Inc.— Acquired - Sep 8, 2021
Kadmon— Acquired
- Dec 1, 2021
Origimm— Acquired
- Dec 19, 2021
Origimm Biotechnology GmbH— Acquired
- Dec 21, 2021
Amunix— Acquired
- Dec 31, 2021
Amunix Pharmaceuticals— Acquired
- Jan 23, 2024
Inhibrx, Inc.— Acquired - May 2, 2025
Vigil Neuroscience— Acquired
- Jun 2, 2025
Blueprint Medicines Corporation— Acquired
- Jul 22, 2025
Vicebio— Acquired
Drugs by trial phase (880 distinct, 3240 trials)
Phase 4 (3 own, 206 via acquisition)
Phase 3 (17 own, 235 via acquisition)
Phase 2 (16 own, 246 via acquisition)
Phase 1 (17 own, 106 via acquisition)
Other trials (2 own, 32 via acquisition)
Indications
Approved for
- Addison Disease
- Angina, Unstable
- Arthritis, Rheumatoid
- Asthma
- Atrial Fibrillation
- Atrial Flutter
- Colorectal Neoplasms
- Constipation
- Coronary Artery Disease
- Cystitis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Retinopathy
- Endometriosis
- Fibrocystic Breast Disease
- Gonorrhea
- Heart Failure
- Hereditary Angioedema Types I and II
- Hirsutism
- Hypercholesterolemia
- Hyperlipoproteinemia Type II
- Hypertension
- Irritable Bowel Syndrome
- Macular Edema
- Malaria, Vivax
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Myasthenia Gravis
- Myocardial Infarction
- Peptic Ulcer
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Rhinitis, Allergic, Seasonal
- Sleep Initiation and Maintenance Disorders
- Spasms, Infantile
- Urinary Tract Infections
- Venous Thrombosis
- Wet Macular Degeneration
Studied for
- Acquired Immunodeficiency Syndrome
- Anemia, Sickle Cell
- Asthma
- Bacterial Infections
- Bipolar Disorder
- Carcinoma, Ductal
- Carcinoma, Ovarian Epithelial
- Chickenpox
- Cholera
- Clostridium Infections
- Communicable Diseases
- Cytomegalovirus Infections
- Dengue
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diphtheria
- Dyslipidemias
- Dysmenorrhea
- Encephalitis
- Encephalitis, Japanese
- Fallopian Tube Neoplasms
- Fever
- Gastroenteritis
- Haemophilus Infections
- Hemophilia A
- Hemorrhagic Fevers, Viral
- Hepatitis
- Hepatitis A
- Hepatitis B
- Herpes Genitalis
- Herpes Simplex
- Herpes Zoster
- HIV Infections
- Hyperuricemia
- Immunologic Deficiency Syndromes
- Infarction
- Infections
- Influenza, Human
- Influenza in Birds
- Lung Diseases
- Lung Diseases, Obstructive
- Measles
- Meningitis
- Meningitis, Meningococcal
- Meningococcal Infections
- Multiple Sclerosis
- Myocardial Infarction
- Orthomyxoviridae Infections
- Osteoporosis
- Osteoporosis, Postmenopausal
- Otitis
- Otitis Media
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Pneumococcal Infections
- Pneumonia
- Pneumonia, Pneumococcal
- Poliomyelitis
- Pulmonary Disease, Chronic Obstructive
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Rabies
- Recurrence
- Respiratory Syncytial Virus Infections
- Rotavirus Infections
- Rubella
- Salmonella Infections
- Schizophrenia
- Sclerosis
- Severe Dengue
- Sleep Initiation and Maintenance Disorders
- Tetanus
- Tetany
- Thrombocytopenia
- Tuberculosis
- Tumor Lysis Syndrome
- Typhoid Fever
- Vaginal Diseases
- Vaginosis, Bacterial
- Viremia
- Virus Diseases
- Whooping Cough
- Yellow Fever
Marketed drugs (135)
- nitroglycerin
- heparin
- corticotropin
- theophylline
- insulin glulisine
- bacille calmette-guerin
- diphtheria, tetanus and whole cell pertussis vaccine
- botulism antitoxin bivalent (equine) types a and b
- caplacizumab
- cefotaxime
- chlorthalidone
- cromoglicic acid
- danazol
- eflornithine
- doxylamine
- dronedarone
- eliglustat
- fexofenadine
- tamsulosin
- insulin glargine
Subsidiaries (30 direct, 94 total across the full acquisition tree)
- Ablynx
- Acambis
- Amunix
- Amunix Pharmaceuticals
- Bioverativ Therapeutics Inc.
- BiPar Sciences
- Blueprint Medicines Corporation
- Chattem
- Fovea Pharmaceuticals
- Genzyme
- Inhibrx, Inc.
- Kadmon
- Kiadis Pharma
- Kymab Limited
- Lorex Pharmaceuticals
- Origimm
- Origimm Biotechnology GmbH
- Principia Biopharma, Inc.
- Protein Sciences Corp
- Provention Bio, Inc.
- Sanofi-Synthelabo
- Shantha Biotechnics Limited
- Synthorx, Inc.
- TargeGen
- Tidal Therapeutics
- Topaz Pharmaceuticals Inc
- Translate Bio, Inc.
- VaxDesign
- Vicebio
- Vigil Neuroscience
- AnorMED L2
- Aventis L2
- Bioenvision L2
- Biomatrix, Inc L2
- Bone Care International L2
- Cell Genesys L2
- Celmed Biosciences L2
- CytoSen L2
- Focal, Inc L2
- GelTex Pharmaceuticals L2
- ILEX L2
- Lengo Therapeutics L2
- L'Oreal L2
- Novazyme Pharmaceuticals L2
- Peptimmune L2
- PharmaGenics L2
- Sangstat Medical Corporation L2
- Sanofi L2
- Three Rivers Pharmaceuticals L2
- True North Therapeutics L2
- Verigen AG L2
- Chinoin L3
- Clin Midy L3
- Hoechst Marion Roussel L3
- Imtix L3
- Kodak L3
- Rhone-Poulenc Rorer L3
- Synthelabo L3
- Applied Immunesciences L4
- Clin Comar L4
- Fisons L4
- Hoechst L4
- Laboratoires Dausse L4
- Laboratoires Delalande L4
- Laboratoires Midy L4
- Laboratoires Robert & Carriere L4
- Marion Merrell Dow L4
- Rhone Poulenc L4
- Rorer L4
- Sterling-Winthrop L4
- Byla Laboratories L5
- Comar & Co. L5
- Connaught Laboratories L5
- Frederick Stearns & Co. L5
- Laboratoires Clin L5
- Lloyd Brothers Pharmacists Inc L5
- Marion Laboratories L5
- Merrell Dow L5
- Pasteur Merieux L5
- Poulenc Freres L5
- Revlon L5
- Roussel-Uclaf L5
- Society of Rhone Chemical Factories L5
- Sterling Drug L5
- Theraplix L5
- Winthrop Chemical L5
- George A. Breon & Co. L6
- Greyhound Corp L6
- Hed Pharmaceuticals L6
- Laboratorios Grossman SA L6
- Merieux Institute L6
- Nysco Laboratories L6
- Sterling Remedy Company L6
- US Vitamin and Pharmaceutical Corporation L6
Recent trials (50)
- NCT06824779CollaboratorPhase 4Oct 31, 2025
- NCT07222059Lead sponsorPhase 3Oct 23, 2025
- NCT07013747Lead sponsorPhase 1/Phase 2Jul 3, 2025
- NCT06838000Lead sponsorPhase 3Feb 28, 2025
- NCT06744205Lead sponsorPhase 1/Phase 2Jan 7, 2025
- NCT06736041Lead sponsorPhase 3Dec 16, 2024
- NCT06727058Lead sponsorPhase 1/Phase 2Dec 9, 2024
- NCT06705140Lead sponsorPhase 3Nov 26, 2024
- NCT06686654Lead sponsorPhase 1/Phase 2Nov 11, 2024
- NCT06641180Lead sponsorPhase 3Nov 4, 2024
- NCT06647407Lead sponsorPhase 1/Phase 2Oct 28, 2024
- NCT06583031Lead sponsorPhase 1Oct 9, 2024
- NCT06604767Lead sponsorPhase 1Sep 17, 2024
- NCT06507553Lead sponsorPhase 1Aug 12, 2024
- NCT06397768Lead sponsorPhase 3May 13, 2024
Details
- Founded
- Leiden, NL Jun 1, 1991
- First NDA
- Dec 31, 1991
- Last known activity
- Oct 31, 2025
Designations held
- Orphan drug
- Fast track
- Priority review
- Breakthrough therapy
Notes
--- Notes from Sanofi Pasteur: previously named Aventis Pasteur --- --- Pre-folding founded info: 2004-01-01 Gentilly None France https://pbs.twimg.com/profile_images/902108011442966528/ZNRgVS1c_400x400.jpg ---